Valuation: KDventures AB

Market Cap 102M 10.17M 9.22M 8.53M 7.69M 14.5M 959M 15.01M 40.62M 512M 38.18M 37.37M 1.63B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 102M 10.17M 9.22M 8.53M 7.69M 14.5M 959M 15.01M 40.62M 512M 38.18M 37.37M 1.63B EV / Sales 2026 *
-0.22x
EV / Sales 2027 * 1.52x
Free-Float
52.57%
Yield 2026 *
-
Yield 2027 * -
1 day+4.89%
1 week+3.81%
Current month-39.87%
1 month-44.36%
3 months-41.12%
6 months-52.80%
Current year-67.52%
1 week 0.13
Extreme 0.128
0.14
1 month 0.13
Extreme 0.128
0.27
Current year 0.13
Extreme 0.128
0.45
1 year 0.13
Extreme 0.128
0.84
3 years 0.13
Extreme 0.128
1.95
5 years 0.13
Extreme 0.128
8.4
10 years 0.13
Extreme 0.128
11.24
Manager TitleAgeSince
Chief Executive Officer 61 2017-05-31
Director of Finance/CFO 58 2022-09-30
Chief Investment Officer - -
Director TitleAgeSince
Director/Board Member 33 2017-11-27
Director/Board Member 57 2021-02-18
Chairman 50 2024-12-17
Date Insider Type Main position Quantity % Market Cap. Importance
3/27/23 Buy

General Counsel

50,000 0.0187%
9/30/22 Buy

General Counsel

40,187 0.0150%
3/8/22 Buy

Chairman

64,001 0.0367%
Change 5-day change 1-year change 3-year change Capi.($)
+4.89%+3.81%-82.34%-91.47% 10.17M
+0.52%+3.74%+15.59%+72.52% 189B
+0.56%+1.80%+31.74%+81.04% 146B
+0.41%+3.85%+38.86%+229.42% 103B
+1.39%+0.58%-15.02%+15.26% 96.12B
-1.50%-0.09%-5.39%+86.01% 91.51B
+0.87%+1.63%-18.24%+47.64% 87.47B
+0.26%-1.79%+1.48%+59.95% 82.38B
+1.75%+5.76%-5.46%+41.97% 72.9B
-0.14%+4.77%+48.45%+148.75% 47.19B
Average +0.90%+1.25%+0.97%+69.11% 92B
Weighted average by Cap. +0.47%+1.95%+11.00%+84.89%

Financials

2026 *2027 *
Net sales -476M -47.31M -42.88M -39.66M -35.78M -67.43M -4.46B -69.81M -189M -2.38B -178M -174M -7.56B 67.4M 6.69M 6.07M 5.61M 5.06M 9.54M 631M 9.88M 26.73M 337M 25.12M 24.59M 1.07B
Net income -497M -49.35M -44.72M -41.36M -37.32M -70.33M -4.65B -72.81M -197M -2.49B -185M -181M -7.89B 45.4M 4.51M 4.09M 3.78M 3.41M 6.43M 425M 6.65M 18M 227M 16.92M 16.56M 721M
Net Debt - -
Projected Income Statement - Annual - KDventures AB
Logo KDventures AB
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
Employees
7
Date Price Change Volume
26-11-16 SEK 0.1416 +4.89% 2,367,649
26-11-13 SEK 0.1350 +3.85% 1,726,503
26-11-12 SEK 0.1300 -1.81% 1,431,086
26-11-11 SEK 0.1324 -2.36% 920,556
26-11-10 SEK 0.1356 -0.59% 521,880

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - KDventures AB
  1. Stock Market
  2. Stocks
  3. KDV B Stock